Ritwik Sinha
TitleCited byYear
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who …
K Porkka, HJ Khoury, RL Paquette, Y Matloub, R Sinha, JE Cortes
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
1522010
Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)
MJ Mauro, M Baccarani, F Cervantes, JH Lipton, Y Matloub, R Sinha, ...
Journal of Clinical Oncology 26 (15_suppl), 7009-7009, 2008
912008
Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study
BA Rybicki, R Sinha, S Iyengar, C Gray-McGuire, RC Elston, MC Iannuzzi
Genes and immunity 8 (5), 379, 2007
352007
Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP)
M Baccarani, G Rosti, G Saglio, J Cortes, R Stone, DW Niederwieser, ...
Blood 112 (11), 450-450, 2008
342008
Predicting reactions to short-text posts
BV Srinivasan, A Natarajan, R Sinha, V Gupta, SV Revankar, B Ravindran
US Patent 9,256,826, 2016
312016
Genetic characterization and fine mapping of susceptibility loci for sarcoidosis in African Americans on chromosome 5
C Gray-McGuire, R Sinha, S Iyengar, C Millard, BA Rybicki, RC Elston, ...
Human genetics 120 (3), 420-430, 2006
312006
Identification of genes and haplotypes that predict rheumatoid arthritis using random forests
R Tang, JP Sinnwell, J Li, DN Rider, M de Andrade, JM Biernacka
BMC proceedings 3 (7), S68, 2009
302009
Tailgate seat apparatus
GP Duvall Jr
US Patent 6,588,822, 2003
29*2003
Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study
LTBY PLZF, RIS MEDIATED
Assistant Editors 93 (s1), 372, 2008
222008
Multiple testing in the genomics era: findings from Genetic Analysis Workshop 15, Group 15
LJ Martin, JG Woo, CL Avery, HS Chen, KE North, Group 15
Genetic epidemiology 31 (S1), S124-S131, 2007
172007
Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal …
A Hochhaus, MC Müller, J Radich, S Branford, B Hanfstein, P Rousselot, ...
Blood 112 (11), 1095-1095, 2008
162008
A non-parametric approach to the multi-channel attribution problem
MM Yadagiri, SK Saini, R Sinha
International Conference on Web Information Systems Engineering, 338-352, 2015
132015
The affected-/discordant-sib-pair design can guarantee validity of multipoint model-free linkage analysis of incomplete pedigrees when there is marker-marker disequilibrium
C Xing, R Sinha, G Xing, Q Lu, RC Elston
The American Journal of Human Genetics 79 (2), 396-401, 2006
112006
Estimating the incremental effects of interactions for marketing attribution
R Sinha, S Saini, N Anadhavelu
2014 International Conference on Behavioral, Economic, and Socio-Cultural …, 2014
102014
Marketing channel attribution
R Sinha, SK Saini, N Anandhavelu
US Patent App. 14/508,141, 2016
92016
Probabilistic deduplication of anonymous web traffic
R Saha Roy, R Sinha, N Chhaya, S Saini
Proceedings of the 24th International Conference on World Wide Web, 103-104, 2015
82015
Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib …
MWN Deininger, MJ Mauro, Y Matloub, R Sinha, L Ploughman, D Liu, ...
Blood 112 (11), 3236-3236, 2008
82008
Haseman Elston regression in ascertained samples: Importance of dependent variable and mean correction factor selection
R Sinha, C Gray-McGuire
Human heredity 65 (2), 66-76, 2008
82008
Will your facebook post be engaging?
BV Srinivasan, A Natarajan, R Sinha, V Gupta, S Revankar, B Ravindran
Proceedings of the 1st workshop on User engagement optimization, 25-28, 2013
72013
Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance …
K Porkka, HJ Khoury, R Paquette, Y Matloub, D Liu, R Sinha, J Cortes
Blood 112 (11), 3242-3242, 2008
72008
The system can't perform the operation now. Try again later.
Articles 1–20